Tvardi Therapeutics Inc (TVRD)

10:28 AM

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com India

10:28 AM

07:38 AM

Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com

07:38 AM

07:04 AM

Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India

07:04 AM

May 20, 2025

Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent

May 20, 2025

May 15, 2025

BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com

May 15, 2025

May 15, 2025

BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com

May 15, 2025

May 14, 2025

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN

May 14, 2025

May 14, 2025

Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter

May 14, 2025

May 13, 2025

Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune

May 13, 2025

May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025

May 13, 2025

Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025

May 09, 2025

Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView

May 09, 2025

May 06, 2025

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire

May 06, 2025

May 01, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada

May 01, 2025

Apr 30, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com

Apr 30, 2025

Apr 23, 2025

Form 8-KCurrent report - ADVFN

Apr 23, 2025

Apr 17, 2025

TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia

Apr 17, 2025

Apr 16, 2025

Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq

Apr 16, 2025

Apr 16, 2025

TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView

Apr 16, 2025

Apr 16, 2025

Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Apr 16, 2025

Apr 15, 2025

Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks

Apr 15, 2025

Apr 15, 2025

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal

Apr 15, 2025

Apr 14, 2025

Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire

Apr 14, 2025

Apr 14, 2025

Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan

Apr 14, 2025

Apr 13, 2025

Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN

Apr 13, 2025

Apr 11, 2025

Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks

Apr 11, 2025

Apr 02, 2025

Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India

Apr 02, 2025

Apr 01, 2025

Cara Therapeutics approves merger and stock plans - Investing.com

Apr 01, 2025

Mar 31, 2025

Shareholders sue to block Stamford-based Cara Therapeutics’ proposed merger with Houston biopharma firm - Hartford Business Journal

Mar 31, 2025

Mar 24, 2025

Cara Therapeutics announces merger with Tvardi Therapeutics - Investing.com

Mar 24, 2025

Mar 19, 2025

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research - Yahoo Finance

Mar 19, 2025

Mar 04, 2025

Cara Therapeutics executive Scott Terrillion sells $775 in stock - Investing.com

Mar 04, 2025

Feb 20, 2025

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire

Feb 20, 2025

Feb 19, 2025

Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 19, 2025

Feb 06, 2025

Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - Investing.com

Feb 06, 2025

Jan 19, 2025

Cara Therapeutics regains Nasdaq compliance By Investing.com - Investing.com India

Jan 19, 2025

Jan 18, 2025

Cara Therapeutics regains Nasdaq compliance - Investing.com

Jan 18, 2025

Jan 02, 2025

Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World

Jan 02, 2025

Dec 31, 2024

Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com

Dec 31, 2024

Dec 30, 2024

Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal

Dec 30, 2024

Dec 27, 2024

Cara Therapeutics enacts reverse stock split - Investing.com

Dec 27, 2024

Dec 18, 2024

Stamford’s Cara Therapeutics to merge with Houston biopharma firm - Hartford Business Journal

Dec 18, 2024

Oct 02, 2024

Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire

Oct 02, 2024

Sep 27, 2024

STAT3 inhibitors named in Vividion Therapeutics patent - BioWorld MedTech

Sep 27, 2024

Jul 31, 2024

Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference - Business Wire

Jul 31, 2024

Jul 09, 2024

Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts - GlobeNewswire

Jul 09, 2024

Mar 26, 2024

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors - Business Wire

Mar 26, 2024

Nov 21, 2023

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference - Business Wire

Nov 21, 2023